SK286079B6 - Použitie kombinácie metabolického derivátu loratadínu a pseudoefedrínu na výrobu liečiva na liečenie kašľa a iných ochorení - Google Patents

Použitie kombinácie metabolického derivátu loratadínu a pseudoefedrínu na výrobu liečiva na liečenie kašľa a iných ochorení Download PDF

Info

Publication number
SK286079B6
SK286079B6 SK61-2005A SK612005A SK286079B6 SK 286079 B6 SK286079 B6 SK 286079B6 SK 612005 A SK612005 A SK 612005A SK 286079 B6 SK286079 B6 SK 286079B6
Authority
SK
Slovakia
Prior art keywords
loratadine
dcl
treatment
pharmaceutically acceptable
cough
Prior art date
Application number
SK61-2005A
Other languages
English (en)
Slovak (sk)
Inventor
A. K. Gunnar Aberg
John R. Mccullough
Emil R. Smith
Original Assignee
Sepracor, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23443929&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286079(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sepracor, Inc. filed Critical Sepracor, Inc.
Publication of SK286079B6 publication Critical patent/SK286079B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK61-2005A 1994-12-30 1995-12-11 Použitie kombinácie metabolického derivátu loratadínu a pseudoefedrínu na výrobu liečiva na liečenie kašľa a iných ochorení SK286079B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/366,651 US5595997A (en) 1994-12-30 1994-12-30 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
PCT/US1995/015995 WO1996020708A1 (en) 1994-12-30 1995-12-11 Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine

Publications (1)

Publication Number Publication Date
SK286079B6 true SK286079B6 (sk) 2008-03-05

Family

ID=23443929

Family Applications (3)

Application Number Title Priority Date Filing Date
SK888-97A SK284834B6 (sk) 1994-12-30 1995-12-11 Použitie metabolického derivátu loratadínu na výrobu liečiva na liečenie alergickej nádchy a iných chorôb
SK61-2005A SK286079B6 (sk) 1994-12-30 1995-12-11 Použitie kombinácie metabolického derivátu loratadínu a pseudoefedrínu na výrobu liečiva na liečenie kašľa a iných ochorení
SK50010-2007A SK287257B6 (sk) 1994-12-30 1995-12-11 Použitie kombinácie metabolického derivátu loratadínu a nesteroidnej protizápalovej látky alebo nenarkotického analgetika na výrobu liečiva na liečenie kašľa a iných ochorení

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK888-97A SK284834B6 (sk) 1994-12-30 1995-12-11 Použitie metabolického derivátu loratadínu na výrobu liečiva na liečenie alergickej nádchy a iných chorôb

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK50010-2007A SK287257B6 (sk) 1994-12-30 1995-12-11 Použitie kombinácie metabolického derivátu loratadínu a nesteroidnej protizápalovej látky alebo nenarkotického analgetika na výrobu liečiva na liečenie kašľa a iných ochorení

Country Status (22)

Country Link
US (2) US5595997A (es)
EP (3) EP1712232A1 (es)
JP (1) JP4237822B2 (es)
KR (1) KR100442675B1 (es)
CN (2) CN1935141B (es)
AT (1) ATE339956T1 (es)
AU (1) AU707541B2 (es)
BR (1) BR9510129A (es)
CA (1) CA2208836C (es)
CZ (1) CZ293068B6 (es)
DE (2) DE799037T1 (es)
DK (1) DK0799037T3 (es)
ES (1) ES2144980T3 (es)
FI (1) FI972781A (es)
HK (1) HK1008185A1 (es)
HU (1) HU229871B1 (es)
MX (1) MX9704793A (es)
NO (3) NO317555B1 (es)
NZ (1) NZ300398A (es)
PT (1) PT799037E (es)
SK (3) SK284834B6 (es)
WO (1) WO1996020708A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0707475T3 (da) * 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US7214683B1 (en) * 1994-12-30 2007-05-08 Sepracor Inc. Compositions of descarboethoxyloratadine
US7211582B1 (en) * 1994-12-30 2007-05-01 Sepracor Inc. Methods for treating urticaria using descarboethoxyloratadine
KR19990082367A (ko) * 1996-02-08 1999-11-25 폴락 돈나 엘. 치료 방법 및 약제학적 조성물
WO1998018470A1 (en) * 1996-10-31 1998-05-07 Schering Corporation Composition, for the treatment of asthma, containing loratadine and a decongestant
US6308328B1 (en) 1997-01-17 2001-10-23 Scientific-Atlanta, Inc. Usage statistics collection for a cable data delivery system
PE71699A1 (es) * 1997-02-07 1999-08-03 Sepracor Inc Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra
AU776837B2 (en) * 1997-02-07 2004-09-23 Sunovion Pharmaceuticals Inc. Lactose-free non-hygroscopic and anhydrous pharmaceutical compositions of descarboethoxyloratadine
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
US5939426A (en) * 1997-02-28 1999-08-17 Sepracor Inc. Methods for treating urinary incontinence using descarboethoxyloratadine
WO1999032125A1 (en) * 1997-12-23 1999-07-01 Schering Corporation Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine
US6140337A (en) 1997-12-23 2000-10-31 Schering Corporation Methods for the treatment of mental disorders
DE69919789T2 (de) * 1998-06-30 2005-09-08 Pfizer Products Inc., Groton Loratadin zur Verwendung als Antiarrhythmikum
EP1380297B1 (en) * 1998-07-10 2009-05-27 Schering Corporation 8-chloro-6,11-dihydro-11-(4-piperidylidene)-5H-benzo[5,6]-cyclo-hepta[1,2-b]pyridine oral compositions
PA8481801A1 (es) * 1998-09-10 2000-09-29 Schering Corp Metodos y composiciones para tratar sinusitis, otitis media y otros desordenes relacionados usando antihistaminas
AU3924500A (en) * 1999-03-29 2000-10-16 Schering Corporation Methods and compositions for treating allergic and related disorders using fluorinated descarboethoxyloratadine
US6100274A (en) * 1999-07-07 2000-08-08 Schering Corporation 8-chloro-6,11-dihydro-11- ](4-piperidylidine)-5H-benzo[5,6]cyclohepta[1,2-bpyridine oral compositions
WO2001021161A2 (en) * 1999-09-21 2001-03-29 Schering Corporation Use of desloratadine for treating allergic and inflammatory conditions
WO2001021162A2 (en) * 1999-09-22 2001-03-29 Schering Corporation Treating allergic and inflammatory conditions using desloratadine
CA2383970A1 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
US6114346A (en) 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine
WO2001045668A2 (en) * 1999-12-20 2001-06-28 Schering Corporation Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine
AU2276801A (en) 1999-12-20 2001-07-03 Schering Corporation Extended release oral dosage composition
EP1239859A2 (en) * 1999-12-21 2002-09-18 Schering Corporation Use of desloratadine for treating allergic and inflammatory conditions in pediatric patients
AU3800601A (en) * 2000-02-03 2001-08-14 Schering Corporation Treating allergic and inflammatory conditions
US7405223B2 (en) * 2000-02-03 2008-07-29 Schering Corporation Treating allergic and inflammatory conditions
EP1267870A2 (en) * 2000-04-07 2003-01-02 Schering Corporation Inhibition of cytokine generation
AU2002256967A1 (en) * 2000-10-30 2002-09-12 Schering Corporation Treating or reducing the risk of cardiovascular disease
AU2002227240A1 (en) * 2000-10-30 2002-05-15 Schering Corporation Treatment and method using loratadine and montelukast
AU2002220248A1 (en) * 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
US6599914B2 (en) * 2001-04-24 2003-07-29 Schering Corporation Inhibition of cytokine generation
US20030236275A1 (en) * 2002-06-20 2003-12-25 Schering Corporation Treatment methods of nasal congestion and nasal obstruction
US6720002B2 (en) * 2001-07-20 2004-04-13 R.P. Scherer Technologies, Inc. Antihistamine formulations for soft capsule dosage forms
JP4394443B2 (ja) * 2001-10-17 2010-01-06 久光製薬株式会社 経皮吸収型製剤
US6863901B2 (en) 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
PL369630A1 (en) * 2001-12-05 2005-05-02 Alcon, Inc. Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
US20030004179A1 (en) * 2002-05-21 2003-01-02 Affrime Melton B Treating allergic and inflammatory conditions
WO2004012738A1 (en) * 2002-08-05 2004-02-12 Sandoz Ag Novel salt and polymorphs of desloratadine hemifumarate
EP1542986B1 (en) * 2002-09-24 2007-01-24 Morepen Laboratories Ltd. Process for the production of desloratadine
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
RS20070008A (en) * 2004-07-07 2008-11-28 Egis Gyogyszergyar Rt., New pseudopolymorph of desloratidine formed with carbon dioxide
US20070281960A1 (en) * 2004-07-16 2007-12-06 Amar Lulla Anti-Histaminic Composition
US20060154948A1 (en) * 2005-01-12 2006-07-13 Schering Corporation Treating allergic and inflammatory conditions
CA2541045A1 (en) * 2006-03-24 2007-09-24 Pharmascience Inc. A descarbonylethoxyloratadine containing pharmaceutical composition
NZ573173A (en) 2006-06-01 2012-03-30 Msd Consumer Care Inc Phenylephrine pharmaceutical formulation and compositions for colonic absorption
WO2008105920A1 (en) * 2007-02-28 2008-09-04 Collegium Pharmaceutical, Inc. Antihistamine combination
WO2009020620A1 (en) * 2007-08-06 2009-02-12 Bridge Pharma, Inc. Synergisms between repartitioning and immunomodulating compounds
AU2008302190A1 (en) * 2007-09-18 2009-03-26 Stephen Wills Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
US8315815B2 (en) 2008-12-30 2012-11-20 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
US8321151B2 (en) 2008-12-30 2012-11-27 The Invention Science Fund I, Llc Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity
US8073633B2 (en) * 2008-12-30 2011-12-06 The Invention Science Fund I, Llc Computational methods and systems for suggesting modulators of CYP450 as treatment options
AR077101A1 (es) 2009-06-16 2011-08-03 Schering Corp Esteroides de heteroarilo (3,2-c), como agonistas de receptor glucocorticoide, composiciones y usos de los mismos
ATE525064T1 (de) 2009-07-01 2011-10-15 Tiefenbacher Alfred E Gmbh & Co Kg Pharmazeutische zusammensetzung mit desloratadin
CA2690490C (en) 2010-01-19 2012-06-26 Accucaps Industries Limited Pharmaceutical formulations of loratadine for encapsulation and combinations thereof
US10383894B2 (en) * 2010-03-17 2019-08-20 Lutran Industries, Inc. Human medicinal treatment using salt of peroxymonosulfuric acid
US8778971B2 (en) 2012-10-23 2014-07-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in companion animals
US8557846B1 (en) 2012-10-23 2013-10-15 Bridge Pharma, Inc. Medicinal treatment of dermal diseases in dogs
US20140120121A1 (en) 2012-10-30 2014-05-01 Bridge Pharma, Inc. Medicinal treatment of atopic inflammatory diseases
US20150272941A1 (en) 2012-10-30 2015-10-01 Bridge Pharma, Inc. Medicinal treatment of chronic pulmonary inflammatory diseases with norketotifen
US9345697B2 (en) 2013-08-06 2016-05-24 Bridge Pharma, Inc. Methods of treatment of non-histaminic pruritus
US9138431B2 (en) 2013-08-06 2015-09-22 Bridge Pharma, Inc. Methods of treatment of histamine H-4 receptor-related pruritus
US9439895B2 (en) 2013-08-06 2016-09-13 Bridge Pharma, Inc. Methods of treating pruritic conditions mediated through non-histaminergic mechanisms in diabetic patients
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4282233B1 (en) 1980-06-19 2000-09-05 Schering Corp Antihistaminic 11-(4-piperidylidene)-5h-benzoÄ5,6Ü-cyclohepta-Ä1,2Ü-pyridines
JPS61501205A (ja) * 1984-02-15 1986-06-19 シェリング・コ−ポレ−ション ８↓−クロル↓−６，１１↓−ジヒドロ↓−１１↓−（４↓−ピペリジリデン）↓−５Ｈ↓−ベンゾ〔５，６〕シクロヘプタ〔１，２−ｂ〕ピリジンおよびその塩、これらの化合物の製造方法、ならびにこれらの化合物を含有する医薬組成物
US4804666A (en) * 1985-08-14 1989-02-14 Schering Corporation Antiallergic 6,11-dihydro-11-(4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5019591A (en) * 1989-02-17 1991-05-28 Pennsylvania Research Corporation Method for treating retinopathy and other small vessel disorders associated with diabetes
IL98572A (en) * 1990-06-22 1995-07-31 Schering Corp Bite-benzo or benzopyrido compounds Cyclohepta piperidine, piperidylidene and piperazine, preparations and methods of use.
CA2098198A1 (en) * 1990-12-18 1992-06-18 Ann Christie King Agents for potentiating the effects of antitumour agents and combating multiple drug resistance

Also Published As

Publication number Publication date
DE69535234D1 (de) 2006-11-02
EP1078633A2 (en) 2001-02-28
EP1078633A3 (en) 2001-03-07
JP4237822B2 (ja) 2009-03-11
US5731319A (en) 1998-03-24
KR100442675B1 (ko) 2004-10-14
CN1935141B (zh) 2013-04-24
SK284834B6 (sk) 2005-12-01
SK88897A3 (en) 1998-02-04
NO20110077L (no) 1997-08-19
BR9510129A (pt) 1997-12-30
US5595997A (en) 1997-01-21
CA2208836A1 (en) 1996-07-11
HU229871B1 (en) 2014-11-28
NO317555B1 (no) 2004-11-15
AU707541B2 (en) 1999-07-15
CN1267098C (zh) 2006-08-02
ATE339956T1 (de) 2006-10-15
AU4512696A (en) 1996-07-24
CN1176598A (zh) 1998-03-18
JPH10512240A (ja) 1998-11-24
CA2208836C (en) 2001-12-04
EP0799037B1 (en) 2006-09-20
CZ293068B6 (cs) 2004-02-18
PT799037E (pt) 2006-12-29
ES2144980T1 (es) 2000-07-01
MX9704793A (es) 1997-10-31
NO330421B1 (no) 2011-04-11
EP0799037A1 (en) 1997-10-08
DE69535234T2 (de) 2007-09-13
WO1996020708A1 (en) 1996-07-11
DE799037T1 (de) 2000-10-05
NO20020211D0 (no) 2002-01-15
EP0799037A4 (en) 1998-05-06
NO973023L (no) 1997-08-19
HK1008185A1 (en) 1999-05-07
CZ202697A3 (cs) 1998-03-18
DK0799037T3 (da) 2007-02-12
CN1935141A (zh) 2007-03-28
HUT77315A (hu) 1998-03-30
FI972781A (fi) 1997-08-27
NO20020211L (no) 1997-08-19
NZ300398A (en) 2001-04-27
EP1712232A1 (en) 2006-10-18
ES2144980T3 (es) 2007-03-16
NO973023D0 (no) 1997-06-27
SK287257B6 (sk) 2010-05-07
FI972781A0 (fi) 1997-06-27

Similar Documents

Publication Publication Date Title
SK286079B6 (sk) Použitie kombinácie metabolického derivátu loratadínu a pseudoefedrínu na výrobu liečiva na liečenie kašľa a iných ochorení
US6054463A (en) Methods for treating dermatitis using descarboethoxyloratadine
EP0975344A1 (en) Use of descarboethoxyloratadine for the manufacture of a medicament for the treatment of urinary incontinence, motion sickness and vertigo
US20010053787A1 (en) Compositions for treating alergic and other disorders using norastemizole in combination with other active ingredients
US7214684B2 (en) Methods for the treatment of allergic rhinitis
US7214683B1 (en) Compositions of descarboethoxyloratadine
MXPA00009464A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina
MXPA00009454A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina
MXPA99007405A (es) Metodo y composiciones para el tratamiento de asma alergico y otros trastornos utilizando descarboetoxiloratadina
MXPA00009465A (es) Metodos y composiciones para tratar rinitis alergica y otros trastornos usando descarboetoxiloratadina

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20151211